Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Enbrel etanercept: Phase III; marketed to treat rheumatoid arthritis (RA) and psoriatic arthritis

In a double-blind, international Phase III trial in 277 patients, 60% of patients given Enbrel

Read the full 155 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE